Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Arch Mal Coeur Vaiss ; 94(2): 144-7, 2001 Feb.
Article in French | MEDLINE | ID: mdl-11265553

ABSTRACT

We report the case of a patient who underwent two cardiopulmonary bypass (CPB) procedures with Orgaran because of heparin-induced thrombocytopenia. A 38 years-old man with ischemic mitral insufficiency was operated for coronary artery bypass and valvular replacement. The CPB was carried out with heparin. Heparin-induced thrombocytopenia occured and was proven immunologically. Two months later, a new valvular replacement was performed because of paravalvular leak due to endocarditis. The Orgaran-CPB protocol was as follows: 5,000 units before cardiopulmonary bypass, 5,000 units in the priming volume, anti-Xa level between 0.9 and 1.1 units/mL, with injection of 1,500 units if necessary, no administration of protamine. One month later, a new valvular replacement was necessary and performed with the same protocol using Orgaran. No bleeding or thrombotic complication occurred. Orgaran is a safe and reliable anti-thrombotic substitute if anti-Xa activity is closely monitored.


Subject(s)
Anticoagulants/therapeutic use , Cardiopulmonary Bypass/methods , Chondroitin Sulfates/therapeutic use , Coronary Artery Bypass , Dermatan Sulfate/therapeutic use , Endocarditis/etiology , Heart Valve Prosthesis Implantation , Heparin/adverse effects , Heparitin Sulfate/therapeutic use , Mitral Valve Insufficiency/surgery , Thrombocytopenia/chemically induced , Adult , Endocarditis/surgery , Heart Valve Prosthesis , Heparin Antagonists/therapeutic use , Humans , Male , Prosthesis Failure , Protamines/therapeutic use , Reoperation , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...